- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Aspergillus fumigatus.
Displaying page 1 of 1.
EudraCT Number: 2016-003921-40 | Sponsor Protocol Number: 2016IF002 | Start Date*: 2017-07-21 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospital of South Manchester NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis | |||||||||||||||||||||||||||||||||
Medical condition: Chronic Pulmonary Aspergillosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000243-87 | Sponsor Protocol Number: PC_ASP_003 | Start Date*: 2018-11-19 | |||||||||||
Sponsor Name:Pulmocide Ltd | |||||||||||||
Full Title: An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection. | |||||||||||||
Medical condition: Pulmonary aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000244-26 | Sponsor Protocol Number: PC-ASP-004 | Start Date*: 2018-08-21 | ||||||||||||||||
Sponsor Name:Pulmocide Ltd | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast... | ||||||||||||||||||
Medical condition: Pulmonary aspergillosis and candidiasis of lung | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004725-23 | Sponsor Protocol Number: Penta-STs-001 | Start Date*: 2021-10-05 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Administration of rapidly generated multipathogen-specific T-Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus fumigatus infections post Allogeneic Stem Cell Transplant | ||
Medical condition: Hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000240-26 | Sponsor Protocol Number: PC_ASP_002 | Start Date*: 2019-05-17 | |||||||||||
Sponsor Name:Pulmocide Ltd | |||||||||||||
Full Title: An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipi... | |||||||||||||
Medical condition: Pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005003-33 | Sponsor Protocol Number: WSA-CS-003 | Start Date*: 2008-06-26 | |||||||||||
Sponsor Name:Astellas Global Pharma Development, Inc | |||||||||||||
Full Title: Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
Medical condition: Invasive fungal disease caused by Aspergillus species in patients with renal impairment as well as disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011452-21 | Sponsor Protocol Number: | Start Date*: 2009-09-18 |
Sponsor Name:University Hospitals of Leicester NHS trust | ||
Full Title: Study of the effectiveness of Voriconazole in the treatment of Aspergillus fumigatus associated asthma | ||
Medical condition: Asthma with sensitization to aspergillus and isolation in sputum. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000627-40 | Sponsor Protocol Number: IA-DUET | Start Date*: 2020-12-28 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET) | |||||||||||||
Medical condition: Invasive aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002619-24 | Sponsor Protocol Number: R668-ABPA-1923 | Start Date*: 2020-09-08 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis | |||||||||||||
Medical condition: Allergic bronchopulmonary aspergillosis (ABPA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) FR (Prematurely Ended) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002949-11 | Sponsor Protocol Number: 601-0014 | Start Date*: 2019-08-05 | |||||||||||
Sponsor Name:Pulmatrix, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PU... | |||||||||||||
Medical condition: Asthma with Allergic Bronchopulmonary Aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005321-78 | Sponsor Protocol Number: CQAW039X2201 | Start Date*: 2013-04-24 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis | ||
Medical condition: Atopic dermatitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) BE (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021349-36 | Sponsor Protocol Number: VRP100419 (CHDR1018) | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:Verona Pharma plc | |||||||||||||
Full Title: Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor,... | |||||||||||||
Medical condition: Allergic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001698-22 | Sponsor Protocol Number: VRP110330 | Start Date*: 2011-04-29 | |||||||||||
Sponsor Name:Verona Pharma plc | |||||||||||||
Full Title: EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY DOSES OF NEBULISED RPL554 0.018 mg/kg (6X) IN ALLERGIC ASTHMATICS | |||||||||||||
Medical condition: Allergic asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000801-39 | Sponsor Protocol Number: PsAer-IgY | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:Mukoviszidose Institute gGmbH | |||||||||||||
Full Title: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ... | |||||||||||||
Medical condition: Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnorma... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) BE (Completed) IT (Completed) IE (Completed) HU (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003544-20 | Sponsor Protocol Number: 207972 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma w... | |||||||||||||
Medical condition: asthma with allergic fungal airway disease (AFAD). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005048-17 | Sponsor Protocol Number: VRP080415 | Start Date*: 2009-01-27 | ||||||||||||||||
Sponsor Name:Verona Pharma Plc | ||||||||||||||||||
Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics | ||||||||||||||||||
Medical condition: Allergic Asthma and Allergic Rhinitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
